Dinshaw Irani’s top sectoral picks for next market cycle

​And obviously the US facing pharma, if you take a Trump call, there is definitely going to be a pressure going forward as such, so that is why we do not like the US focused pharma companies much and we do not have much exposure there, rather no exposure there as such. We are more focused on to domestic pharma. In a diagnostic space, we got the best player, the top player with us.

More To Explore

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003